Group items tagged

The government has launched the Global AMR Innovation Fund (GAMRIF) on Monday (22 May), under which it has announce up to £39 million fund for antimicrobial resistance (AMR) research. Of this new funding package, up to £24 million over four years has been awarded to bolster the UK's partnership with CARB-X - a global AMR research initiative - to support the continued early development of invaluable new antibiotics, vaccines, rapid diagnostics and other products to combat life threatening drug-resistant infections and prevent death and disease across the world. In addition to the CARB-X grant, GAMRIF is investing £5 million over two years into the Global Antibiotic R&D Partnership (GARDP) to develop - and ensure global access to - new antibiotic treatments against major global health priorities. The announcement comes as Health Minister Will Quince attends the World Health Assembly (WHA) in Geneva, Switzerland, and Development Minister Andrew Mitchell participates in an event on health leadership and climate change alongside the WHA. They will announce the launch of the UK government's Global Health Framework for 2023-2025, as part of Minister Quince's address at the WHA. Health Minister Will Quince said: Antimicrobial resistance is a major threat to global health and has led to millions of tragic deaths per year, but the Global AMR Innovation Fund is supporting cutting-edge research and developing vital new treatments to prevent death and disease across the world.

The UK Department of Health and Social Care (DHSC) has signed a new US$10 million (7.8 million pounds) grant agreement with global non-profit organisation, FIND. This extends the UK government's support to FIND through the Global AMR Innovation Fund (GAMRIF) for another four years. FIND recently announced the GAMRIF funding, which will be used to support its three-pronged strategy to prevent AMR emergence and halt its development. Dr Cassandra Kelly-Cirino, Vice President, Health Programmes at FIND, said: "Lack of essential diagnostics that can be accessed by people when and where they are needed is jeopardizing global efforts to combat AMR everywhere. We are grateful to GAMRIF for the continued support as we work in partnership on this multi-faceted strategy to save lives."

According to the National Health Services (NHS)'s new mandate, pharmaceutical companies seeking to participatign its Antimicrobial Product subscription model must certify to the BSI Kitemark for minimised risk of Antimicrobial Resistance (AMR) This move is part of the NHS's strategy to tackle the growing global threat of AMR by ensuring that antibiotic manufacturers adhere to stringent environmental controls. The NHS antibiotic subscription model is the first of its kind globally, offering pharmaceutical companies a fixed annual fee based on the value and availability of their antimicrobials to the NHS, rather than the quantity consumed. The innovative approach aims to stimulate the development of new antibiotics while addressing the environmental impact of their production. The NHS antibiotic subscription model is a ground-breaking incentive program as the first in the world to pay companies a fixed annual fee for antimicrobials based on the value of the drugs to the NHS, and their availability, instead of the volumes used.

In a collaborative effort to combat the escalating threat of antimicrobial resistance (AMR), UWE Bristol and Bedminster Pharmacy have secured grant funding from the UKRI Regional Innovation Fund (RIF) for a groundbreaking 4-month project. This initiative aims to revolutionise antimicrobial stewardship (AMS) practices at the community pharmacy level, addressing the pressing need for evidence-based approaches in tackling AMR. With antibiotic misuse contributing significantly to the rise of AMR, the project underscores the vital role of community pharmacies in promoting responsible antibiotic use. Mr Ade Williams, Superintendent Pharmacist at Bedminster Pharmacy, emphasised the significance of this endeavour, stating:

The UK government on Thursday (8 May) launched a new plan to tackle antimicrobial resistance (AMR), a global issue that makes infections difficult or impossible to treat. This is the second phase of a series of 5-year national action plans, aimed at supporting the government's 20-year vision to contain and control AMR by 2040. With the launch of this new national action plan, the UK commits to reducing its use of antimicrobials - such as antibiotics, antifungals and antivirals - in humans and animals. Additionally, it aims to strengthen surveillance of drug-resistant infections before they emerge and incentivise industry to develop the next generation of treatments. There are also plans to expand initiatives such as the world-first 'subscription model' for antimicrobials, launched in 2019 as a pilot.

The Association of the British Pharmaceutical Industry (ABPI) has welcomed the National Institute for Health and Care Excellence's leadership in introducing a new approach to the evaluation of antibiotics. On Tuesday (12 April), NICE published a draft guidance to tackle antimicrobial resistance under which two new antimicrobial drugs - cefiderocol and ceftazidime-avibactam - became the first to be made available as part of the UK's innovative subscription-style payment model. Commenting on the announcement of the new draft guidance, Richard Torbett, chief executive of the ABPI, said: "This is an important milestone in the UK's global leadership on AMR. Antibiotics underpin modern medicine, but the increasing threat of antibiotic resistance remains one of the biggest global health challenges we face. "To tackle this, it is critical that the appropriate frameworks are in place for companies to invest the billions of pounds required to discover the new antibiotics needed for patients.

The Association of the British Pharmaceutical Industry (ABPI) has appointed Susan Rienow, country president of Pfizer, as its vice president. "As vice president, she will support the president, Pinder Sahota, general manager and corporate vice president of Novo Nordisk UK, in delivering his priorities. These are improving access to medicines, delivering economic growth and helping to find solutions to big societal challenges such as climate change, AMR, and inequalities," said ABPI in a statement. At Pfizer, Susan leads the organisation to bring the power of innovation, data and technology together to transform healthcare and improve outcomes for patients. She previously led Pfizer UK's vaccines business unit during the Covid-19 pandemic.

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

Thirteen people were arrested following raids at four drug manufacturing units in the Indian states of Gujarat and Rajasthan, resulting in the seizure of mephedrone valued at Rs 230 crore (approximately 22.30 million GBP), according to a news agency report. The Gujarat Anti-Terrorist Squad (ATS) and Narcotics Control Bureau conducted the raids jointly on Friday, prompted by a tip-off received by the ATS indicating that Ahmedabad resident Manoharlal Enani and Kuldeepsinh Rajpurohit from Rajasthan had set up mephedrone manufacturing units, PTI reported on Saturday, quoting an official. As stated in an ATS release obtained by the news agency, the raids were conducted at the units in Sirohi and Jodhpur in Rajasthan and Piplaj village in Gandhinagar and Bhaktinagar industrial area of Amreli district in Gujarat. "The ATS recovered 22.028 kilograms of mephedrone (in solid form) and 124 kilograms of liquid mephedrone, collectively valued at Rs 230 crore(approximately 22.30 million GBP). "Rajpurohit was nabbed during the raid in Gandhinagar and Enani was held from Sirohi," it said.

The Company Chemists' Association (CCA) has urged NHS England to expand the Pharmacy First service by increasing treatment options, adding more conditions, and integrating Independent Prescribing into the service. This would further promote pharmacists as antimicrobial stewards while enhancing patient access to urgent care, it said. Managing patient demand for antibiotics remains a challenge for healthcare professionals, including pharmacists. However, a new report by CCA confirms that pharmacists are acting as responsible providers of antibiotics, in line with Antimicrobial Resistance (AMR) guidelines. The service allows pharmacies to provide advice and treatment, including prescription-only medication, for seven common conditions: earache, uncomplicated urinary tract infections (UTIs) in women, sore throat, sinusitis, infected insect bites, impetigo, and shingles. Patients can access the service via GP referrals or by visiting or contacting a pharmacy directly.